OMX 0407
Alternative Names: OMX-0407Latest Information Update: 19 Jun 2025
At a glance
- Originator iOmx Therapeutics
- Class Antineoplastics
- Mechanism of Action Protein tyrosine kinase inhibitors; Salt-inducible kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 25 Apr 2025 Efficacy data from a phase I trials in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 25 Apr 2025 Pharmacodynamics data from preclinical trials in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 23 Oct 2024 Pharmacodynamics data from a phase I and preclinical trials in Solid tumours presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)